Torrent Pharma Q1 FY27 Results: Revenue Surges 55% to ₹4,921 Crore, India Business Delivers Record Growth
Torrent Pharmaceuticals Limited has announced a robust set of financial results for the first quarter of FY27, driven by record growth in its India business and the successful integration of JB Chemicals & Pharmaceuticals (JB Pharma).
The company reported a 55% year-on-year (YoY) increase in consolidated revenue to ₹4,921 crore, while operating EBITDA climbed 61% to ₹1,664 crore. India remained the biggest growth driver, supported by strong demand across chronic therapies and an expanding product portfolio.
Q1 FY27 Consolidated Financial Highlights
| Particulars | Q1 FY27 | Q1 FY26 | YoY Growth |
|---|---|---|---|
| Revenue from Operations | ₹4,921 crore | ₹3,178 crore | 55% |
| Operating EBITDA* | ₹1,664 crore | ₹1,032 crore | 61% |
| EBITDA Margin | 33.8% | 32.5% | +130 bps |
| Gross Margin | 76.4% | 75.6% | +80 bps |
| Profit After Tax (PAT) | ₹566 crore | ₹548 crore | 3% |
| R&D Spend | ₹172 crore | ₹157 crore | 10% |
*Before exceptional items.
Revenue Crosses ₹4,900 Crore
Torrent Pharma reported consolidated revenue of ₹4,921 crore, marking a 55% YoY increase. The sharp rise was primarily driven by the consolidation of JB Pharma along with healthy organic growth across domestic and international markets.
India Business Delivers Record Organic Growth
The company’s base India business delivered one of its strongest quarterly performances.
- India revenue stood at ₹2,157 crore, up 19% YoY, significantly ahead of the 12% growth recorded by the Indian Pharmaceutical Market (IPM).
- Torrent Pharma became the No. 1 company in the Indian cardiac therapy market.
- Generic Semaglutide captured a 36% market share (oral and injectable combined) during the quarter.
International Markets Continue to Grow
Torrent Pharma also reported healthy growth across key overseas markets.
United States
- Revenue increased 36% YoY to ₹418 crore.
- Growth was supported by successful new product launches and one-time business opportunities.
Brazil
- Revenue rose 27% to ₹277 crore.
- According to IQVIA data, Torrent significantly outperformed the Brazilian pharmaceutical market.
Germany
- Revenue increased 3% to ₹318 crore.
- Growth remained affected by supply disruptions at a third-party supplier and lower tender offtake.
JB Pharma Integration Strengthens Growth
Following the merger with JB Chemicals & Pharmaceuticals, the acquired business continued to perform well.
JB Business Highlights
| Metric | Q1 FY27 | YoY Growth |
|---|---|---|
| Revenue | ₹1,201 crore | 10% |
| Operating EBITDA | ₹424 crore | 34% |
| EBITDA Margin | 35.3% | — |
Other highlights include:
- India prescription business (excluding trade generics and contrast media) grew 13%.
- International business expanded 12%.
- CDMO business revenue increased 27% to ₹145 crore.
Financial Performance
According to the consolidated financial statements:
- Profit before tax stood at ₹733 crore.
- Profit after tax reached ₹566 crore.
- Earnings per share (EPS) came in at ₹14.87 for the quarter.
Merger with JB Pharma Completed
Torrent Pharma completed the merger of JB Chemicals & Pharmaceuticals Limited after receiving approval from the National Company Law Tribunal (NCLT). The scheme became effective on July 8, 2026, with an appointed date of January 21, 2026.
The company issued new equity shares to eligible JB Pharma shareholders under the approved share exchange ratio, strengthening Torrent Pharma’s position in the Indian pharmaceutical market.
Management Outlook
Torrent Pharma remains optimistic about future growth, supported by:
- Strong momentum in the Indian pharmaceutical market.
- Leadership in the cardiovascular segment.
- Continued expansion in Brazil and the United States.
- Synergies from the JB Pharma integration.
- Ongoing investments in research and development.
The company believes its diversified business model and expanding product portfolio will continue to support long-term growth.